Y

Y-mAbs Therapeutics
D

YMAB

4.40000
USD
-0.21
(-4.56%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-7
Market Cap
199,301,494
OverviewSignalsIdeasNews
Related Instruments
ABBV
ABBV
-0.290
(-0.16%)
185.210 USD
BMY
BMY
0.005
(0.01%)
46.860 USD
BNTX
BNTX
2.140
(2.05%)
106.620 USD
GILD
GILD
-0.020
(-0.02%)
108.000 USD
I
IMVT
-0.065
(-0.41%)
15.800 USD
LLY
LLY
-21.65
(-2.76%)
763.15 USD
MRNA
MRNA
0.510
(2.01%)
25.920 USD
REGN
REGN
-3.73
(-0.73%)
509.70 USD
VRTX
VRTX
-7.64
(-1.70%)
440.97 USD
More
News
Treasury Yields Decline as Market Anticipates Fed Rate Cuts

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

9 months ago
Economy News
Novo Nordisk Surges in Profit and Sales

Novo Nordisk Surges in Profit and Sales

1 year ago
Stocks News
More

Title: Y/mAbs Therapeutics

Sector: Healthcare
Industry: Biotechnology
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.